Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Director · See Remarks | June 28, 2018 | June 29, 2018 |
| Chrome Holding Co.ME · Entity 76268 | Chief Therapeutics Officer | June 05, 2023 | June 07, 2023 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 07, 2023 | December 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 28, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 293,336 |
Last balance in matching sequence
After 2018-06-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-06-28 · Exercise / conversion · Acquired 132,727 · Balance 248,128 F1: Includes 78,600 Restricted Stock Units. Row 2 · 2018-06-28 · Exercise / conversion · Acquired 45,208 · Balance 293,336 F1: Includes 78,600 Restricted Stock Units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.93 · Expires 2021-06-07 | Direct | 0 |
Reported balance
After 2018-06-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-28 · Exercise / conversion · Disposed 132,727 · Balance 0 F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2026-02-26 | Direct | 32,292 |
Reported balance
After 2018-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-06-28 · Exercise / conversion · Disposed 45,208 · Balance 32,292 F3: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 19, 2016, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 78,600 Restricted Stock Units.
F2: The option is fully vested and exercisable.
F3: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 19, 2016, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date.
Chrome Holding Co.
Report date June 05, 2023 · Filed June 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 221,876 |
Ending reported balance
After 2023-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-05 · Grant · Acquired 44,381 · Balance 237,223 F1: Restricted stock units (the "RSUs") granted under the 23andMe Amended and Restated Annual Incentive Plan and the 23andMe Holding Co. 2021 Incentive Equity Plan (together, the "Plans") as payment of the reporting person's annual incentive bonus for the fiscal year ended March 31, 2023. The RSUs are fully vested at the time of grant and are subject to the terms and conditions of the Plans, the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of 23andMe Holding Co. Row 2 · 2023-06-05 · Tax withholding · Disposed 15,347 · Balance 221,876 F2: The closing price on June 5, 2023, the fair market value used for the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units (the "RSUs") granted under the 23andMe Amended and Restated Annual Incentive Plan and the 23andMe Holding Co. 2021 Incentive Equity Plan (together, the "Plans") as payment of the reporting person's annual incentive bonus for the fiscal year ended March 31, 2023. The RSUs are fully vested at the time of grant and are subject to the terms and conditions of the Plans, the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of 23andMe Holding Co.
F2: The closing price on June 5, 2023, the fair market value used for the transaction date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 99,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date December 07, 2023 · Filed December 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2033-12-06 | Direct | 37,000 |
Reported balance
After 2023-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-07 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-25-017369 · form4-06162025_040605.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-11 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017369 · form4-06162025_040605.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:23 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-24-015754 · form4-06062024_080652.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:23 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015754 · form4-06062024_080652.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 17:17 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-069104 · ownership.xml · derivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:20 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 15,347 | $2.08 | $31,921.76 |
DisclosureSEC source: 0001209191-23-035076 · doc4.xml · nonDerivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,876 F2 · price: The closing price on June 5, 2023, the fair market value used for the transaction date. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:20 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 44,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035076 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,223 F1 · kind: Restricted stock units (the "RSUs") granted under the 23andMe Amended and Restated Annual Incentive Plan and the 23andMe Holding Co. 2021 Incentive Equity Plan (together, the "Plans") as payment of the reporting person's annual incentive bonus for the fiscal year ended March 31, 2023. The RSUs are fully vested at the time of grant and are subject to the terms and conditions of the Plans, the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of 23andMe Holding Co. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:48 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,750 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-23-034390 · doc4.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:48 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034390 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 5,000 shares subject to the Reporting Person's September 9, 2020 RSU grant that will vest in one final installment on September 9, 2023. Read SEC document |
| May 20, 2023 Filed May 23, 2023 16:05 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 4,628 | $1.94 | $8,978.32 |
DisclosureSEC source: 0001209191-23-031655 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,842 F1 · price: The closing price on May 19, 2023, the fair market value used for the transaction date. F2 · balance_after: Includes 5,765 shares acquired under the 23andMe Holding Co. 2021 Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 17:12 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 5,457 | $2.87 | $15,661.59 |
DisclosureSEC source: 0001209191-23-011754 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,705 F1 · price: The closing price on February 17, 2023, the fair market used for the transaction date. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 19:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0000899243-22-039322 · doc4.xml · derivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document |
| November 20, 2022 Filed Nov 22, 2022 16:11 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 4,628 | $2.99 | $13,837.72 |
DisclosureSEC source: 0001209191-22-058361 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,162 F1 · price: The closing price on November 18, 2022, the fair market used for the transaction date. F2 · balance_after: Includes 5,707 shares acquired under the 23andMe Holding Co. 2021 Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 17:00 UTC | Chrome Holding Co. ME · Entity 76268 | SaleClass A Common Stock | 8,753 | $3.64 | $31,860.92 |
DisclosureSEC source: 0001209191-22-047540 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,083 Read SEC document |
| August 20, 2022 Filed Aug 22, 2022 18:12 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 4,628 | $3.33 | $15,411.24 |
DisclosureSEC source: 0001209191-22-047067 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,836 F1 · price: The closing price on August 19, 2022, the fair market used for the transaction date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 16:26 UTC | Chrome Holding Co. ME · Entity 76268 | Tax withholdingClass A Common Stock | 4,627 | $2.82 | $13,048.14 |
DisclosureSEC source: 0001209191-22-033526 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Chief Therapeutics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,464 F1 · price: The closing price on June 1, 2022, the transaction date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014134 · doc4.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014134 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 10,000 shares subject to the Reporting Person's September 9, 2020 RSU grant that will vest in two remaining annual installments of 5,000 shares on each of September 9, 2022 and 2023, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:23 UTC | Chrome Holding Co. ME · Entity 76268 | GrantStock Option (Right to Buy) · Derivative | 471,413 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008865 · doc4.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Head of Therapeutics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,413 Underlying: Class A Common Stock · 471,413 shares Expires 2032-02-09 F2 · derivative.exercise_date: Grant of stock options under the Plan. The stock options vest equally in 1/48 monthly installments commencing on March 9, 2022. The vesting of the options is subject to continued service for the Company, the terms and conditions of the applicable award agreement, and applicable tax withholding obligations. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:23 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 214,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008865 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Head of Therapeutics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,091 F1 · kind: Grant of restricted stock units (the "RSUs") under the 23andMe Holding Co's (the "Company") 2021 Incentive Equity Plan (the "Plan"). The RSUs vest equally in 1/16 quarterly installments commencing on May 20, 2022. The vesting of the RSUs is subject to continued service for the Company, the terms and conditions of the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of the Company. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0000899243-21-018767 · doc4.xml · derivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015499 · doc4.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015499 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes 15,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's September 9, 2020 RSU grant that vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $10.43 | $0.00 |
DisclosureSEC source: 0001209191-20-050208 · doc4.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-09-08 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, however shares purchased pursuant to the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service, as defined in the 2018 EIP, as amended. The shares subject to the option vest in 36 successive equal monthly installments upon completion of each month of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the September 9, 2020 grant date, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050208 · doc4.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Includes 15,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on September 9, 2020. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| May 08, 2020 Filed May 12, 2020 06:31 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0000899243-20-012776 · doc4.xml · derivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-05-07 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 8, 2020. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:23 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0000899243-19-012638 · doc4.xml · derivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2019. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,208 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001140361-18-030785 · doc1.xml · derivative · entry 4 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,292 Underlying: Common Stock · 45,208 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 19, 2016, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | Exercise / conversionStock Option (Right to Buy) · Derivative | 132,727 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-18-030785 · doc1.xml · derivative · entry 3 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,727 shares Expires 2021-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | Exercise / conversionCommon Stock | 45,208 | $3.65 | $165,009.20 |
DisclosureSEC source: 0001140361-18-030785 · doc1.xml · nonDerivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 78,600 Restricted Stock Units. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | Exercise / conversionCommon Stock | 132,727 | $6.93 | $919,798.11 |
DisclosureSEC source: 0001140361-18-030785 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 78,600 Restricted Stock Units. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:19 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-030423 · doc1.xml · derivative · entry 3 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:19 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 744 | $9.59 | $7,134.96 |
DisclosureSEC source: 0001140361-18-030423 · doc1.xml · nonDerivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,401 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer. F2 · balance_after: Includes (i) 1,744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2018 and (ii) 78,600 RSUs. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:19 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 2,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-030423 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,145 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F2 · balance_after: Includes (i) 1,744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2018 and (ii) 78,600 RSUs. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 19:17 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 2,735 | $11.74 | $32,108.90 |
DisclosureSEC source: 0001140361-18-013721 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,151 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 61,500 RSUs. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 20:37 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 4,606 | $10.67 | $49,146.02 |
DisclosureSEC source: 0001140361-18-009969 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,886 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes (i) 4,070 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2017 and November 30, 2017 and (ii) 69,550 RSUs. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:29 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-024051 · doc1.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-02-08 F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 8, 2018, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:29 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024051 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,251 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 78,600 RSUs. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 19:45 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 3,079 | $26.58 | $81,839.82 |
DisclosureSEC source: 0001140361-17-012435 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,422 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 81,675 RSUs. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:21 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.62 | $0.00 |
DisclosureSEC source: 0001140361-17-009249 · doc1.xml · derivative · entry 3 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-02-22 F4 · derivative.exercise_date: The shares subject to the option shall vest on the following schedule: (i) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $30.00 per share; (ii) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $40.00 per share; and (iii) 20% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $55.00 per share, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date and as appropriately adjusted for stock splits, stock dividends, recapitalizations and the like. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:21 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $23.62 | $0.00 |
DisclosureSEC source: 0001140361-17-009249 · doc1.xml · derivative · entry 2 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2026-02-22 F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 22, 2017, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:21 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009249 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,501 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 89,725 RSUs. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 19:39 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 1,696 | $22.76 | $38,600.96 |
DisclosureSEC source: 0001140361-17-008924 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,501 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 49,725 Restricted Stock Units. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:35 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 1,431 | $16.78 | $24,012.18 |
DisclosureSEC source: 0001140361-17-003547 · doc1.xml · nonDerivative · entry 1 Hillan Kenneth J. · CIK 0001600359 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,197 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 53,850 Restricted Stock Units and 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.